JUNE 3, 2010 - Sinapis Pharma Inc. believes that it has a found a way to provide neuroprotection to stroke patients and those with traumatic brain injury using an unlikely benefactor – an intravenous, low-dose form of the neurotoxic drug methamphetamine. ...more...

University of Montana researchers have learned that low doses of methamphetamine given to rodents after strokes reduce brain damage and impairment by 50 percent or more. Now a UM research spinoff company, Sinapis Pharma, intends to start human Phase I clinical trials of the drug application in coming months. ...more...

JACKSONVILLE, Fla., April 12, 2010 /PR Newswire/ -- Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. ...more...

Jan. 29, 2010 -- University of Montana researchers have learned that low doses of methamphetamine given to rodents after strokes reduce brain damage and impairment by 50 percent or more. Now a UM research spinoff company, Sinapis Pharma, intends to start human Phase I clinical trials of the drug application in coming months. ...more...

Dec. 12, 2009 -- If Dave Poulsen’s research gets approval from federal regulators for medical use, Poulsen and his employer, the University of Montana, stand to make a lot of money on meth. ...more...

JACKSONVILLE, Fla., Nov. 17, 2009 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous... ...more...

---

JACKSONVILLE, Fla., Sept. 8, 2009 /PRNewswire/ -- Sinapis Pharma announces that it will present an overview of its stroke and traumatic brain injury treatment data at the Rodman & Renshaw Annual Global Investment Conference at the Palace Hotel in New York City this Friday, September 11, 2009, at 3:15 PM ET. Sinapis has discovered and has patents-pending for a novel use and route of administration of an FDA-approved drug that will be in clinical development in the near future. Further information can be found at www.sinapispharma.com or the conference website www.rodmanandrenshaw.com/conferences.

---

JACKSONVILLE, Fla., Sept. 8, 2009 /PRNewswire/ -- Sinapis Pharma, Inc is pleased to announce the addition of Frederick Frank as a consultant to the company. Mr. Frank will leverage his decades of experience to advise the company on merger and acquisition opportunities and fund raising for clinical trial development. Sinapis Pharma has discovered and is patenting a new therapeutic approach to treating stroke in humans using Methamphetamine in an intravenous (IV) formulation. ...more...

---

The UM researchers working with the Montana Neuroscience Institute are not the type of people one would expect to be pushing methamphetamine. But these respectable-looking scientists are saying that a clinical use for this devastating street drug may have been overlooked. ...more...

MISSOULA, Mont. — Methamphetamine appears to lessen damage to the brains of rats and gerbils that have suffered strokes, a new study by a group of University of Montana scientists shows.

"Methamphetamine is a drug that has been shown to exacerbate stroke damage or make it worse when administered before a stroke," Dave Poulsen, a UM research assistant professor, said in a news release. "But we have seen roughly 80 to 90 percent protection of neurons when administered after a stroke." ...more...